Renalsense Raises $14M Series A Funding To Bolster Global Commercialization And Expand Its Product Line

Nov 22, 2021•over 3 years ago

Amount Raised

$14 Million

Round Type

series a

Jerusalem

Description

RenalSenseTM, a leader in real-time renal diagnostics, today announced it has secured $14M to bolster the global commercialization of its current product, the Clarity RMS, expand clinical validation to additional clinical settings, and advance the release of its next generation products based on its sensor platform. The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.

Company Information

Company

Renal Sense

Location

Jerusalem, Jerusalem District, Israel

About

RenalSense is a privately-owned medical device company dedicated to real-time renal diagnostics. The company's first product, Clarity RMS, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics. RenalSense's next-generation products will provide additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and peri-operative setting. SOURCE RenalSense

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Renalsense Raises $14M Series A Funding To Bolster Global Commercialization And Expand Its Product Line

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information